Research graph
References from Real-world clinical efficacy of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in heavily pretreated platinum-resistant ovarian cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
Cancer statistics, 2025
2025 · External reference
Ovarian cancer: a review
10.1001/jama.2025.9495 · 2025 · External reference
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial
10.1200/jco.2013.51.4489 · 2014 · External reference
Mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer
10.1056/nejmoa2309169 · 2023 · External reference
Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: analysis of KEYNOTE-028
10.1016/j.ygyno.2018.11.017 · 2019 · External reference
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study
10.1093/annonc/mdz135 · 2019 · External reference
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN ovarian 100): an open-label, randomised, phase 3 trial
10.1016/s1470-2045(21)00342-9 · 2021 · External reference
Efficacy and safety of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of recurrent ovarian cancer: a phase 2 nonrandomized clinical trial
10.1001/jamaoncol.2020.5945 · 2021 · External reference
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study
10.1016/s0140-6736(26)00602-1 · 2026 · External reference
Unresolved reference
2017 · External reference
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
10.1016/j.ejca.2008.10.026 · 2009 · External reference
Pembrolizumab in combination with bevacizumab and oral cyclophosphamide in heavily pre-treated platinum-resistant ovarian cancer
10.1136/ijgc-2022-003941 · 2023 · External reference
Efficacy of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of platinum resistant recurrent ovarian cancer: a retrospective observational study
2025 · External reference
Unresolved reference
External reference
Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial
10.1016/s0140-6736(26)00462-9 · 2026 · External reference
Unresolved reference
External reference
